Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

Impact · against what's priced in

The article provides no new catalysts for BMY or LLY, as it focuses on widely known patent cliffs and valuation disparities already reflected in the stocks' trading multiples. It reinforces the existing market consensus that BMY's low P/E is a result of anticipated revenue declines from Opdivo and Eliquis.

LLY+0.00: Already priced in
The price assumes: Current GLP-1 market dominance

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

What matters in this story

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

What matters in this story

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside

How each ticker is affected

Connected tickers

Track these names every morning.

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 29

Roche says divarasib cut risk of death 44% in lung cancer trial

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

What matters in this story

Next reads from the same story arc

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

What matters in this story

Next reads from the same story arc

Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside

How each ticker is affected

Connected tickers

Track these names every morning.

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 29

Roche says divarasib cut risk of death 44% in lung cancer trial

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29